ARCHIVES

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

This article is from The Cancer Letter archive.

Vol. 30 No. 42 | November 5, 2004

Download PDF Visit The Full Archive

Related Articles

Interview With Departing NCI Director; Advice To His Successor.

July 9, 2010

Institute Of Medicine Report Says Insurers Should Pay Patient Care Costs In Clinical Trials

February 24, 1989

Top Management Shifts At Bristol-Myers Squibb Oncology, R&D Units

October 6, 1995

Secret Budget Sessions Ended; HEW Out To Lim. Future NCI Funds

April 2, 1976

QOL Of Young Survivors Equal To Other Children

February 25, 2005

Organ Systems Program Progress, Momentum Threatened During transition, Karr Contends

December 9, 1988